BioSpace News Archive

A study from the University of Minnesota Combat Casualty Training Consortium shows no significant differences between the use of live tissue models and synthetic training models in the learners’ stress level.

Disruption of the refill of patients’ regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.

Researchers have developed a fundamentally new approach to a see-through display for augmented reality, or smart glasses.

CAQH has launched CAQH ProView for Groups, simplifying the way data is shared between delegated provider groups and health plans

FluGen, Inc. announced today that the company’s novel M2 deleted, single replication (M2SR) influenza vaccine was safe and well tolerated, generated a dose-response effect for both humoral and mucosal antibodies, and produced robust T-cell responses in a first-in-human phase 1a trial of 96 healthy volunteers ages 18-49 years.

Apollo Hospitals and Qfix jointly announce a partnership that will allow Indian proton therapy patients to benefit from the very latest in patient-positioning and fixation technology.

Harvest Enterprises Inc. (Harvest), a vertically integrated cannabis company with one of the largest footprints in the U.S., announced it received approval from the Pennsylvania Department of Health to open the first medical marijuana dispensary in Berks County, Pennsylvania.

NuVasive, Inc. (NASDAQ: NUVA), focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will highlight several of its latest spinal innovations to treat complex spinal deformities at the Scoliosis Research Society (SRS) Annual Meeting held October 10-13, 2018

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting to be held November 7-11, 2018 in Washington, D.C.

Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the results of the Phase 3 DUO™ study,